Supha Pharmachem Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Supha Pharmachem Limited's yearly results (2022–2025), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every ₹100 of sales, ₹128 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹5 tied up three years earlier. More money tied up than almost all Healthcare companies in India.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than almost all Healthcare companies in India.
- Cash Cushion Ratio: Debt, after subtracting cash, is 2.0 times its market value (net debt). Lower than almost all Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
₹128For every ₹100 of sales, ₹128 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹5 tied up three years earlier.
More money tied up than almost all Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
—Sales fell 20%
Sales fell 20% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-20% / +669%In 3 years sales changed by -20% while total assets changed by +669%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-25.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than almost all Healthcare companies in India.
Cash Cushion Ratio
2.0× debtDebt, after subtracting cash, is 2.0 times its market value (net debt).
Lower than almost all Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 98% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 98% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Supha Pharmachem Limited owes ₹0.94 for every ₹1 it owns. Net profit fell 93% in the year to Mar 2025, and grew 25% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2025.
P/E ratio
1.9Investors pay ₹1.9 for every ₹1 of Supha Pharmachem Limited's yearly profit, lower than almost all Healthcare companies in India.
P/B ratio
0.21The share price is 0.21 times Supha Pharmachem Limited's book value per share, lower than almost all Healthcare companies in India.
Market cap
₹22 CrThe total market value of all of Supha Pharmachem Limited's shares at today's price (share price × number of shares), smaller than almost all Healthcare companies in India. PosiCap size class: Nano Cap.
Net worth (book value)
₹105 CrWhat Supha Pharmachem Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Sep 2025).
Book value per share
₹1.19Net worth divided by the number of shares. The share price of ₹0.25 is 0.2 times this, which is the P/B above.
Return on equity (ROE)
16.2%Supha Pharmachem Limited earned 16.2% on its shareholders' money over the last year, higher than 61% of Healthcare companies in India.
Owes vs Owns
0.94×Supha Pharmachem Limited owes ₹0.94 for every ₹1 it owns (high), higher than almost all Healthcare companies in India.
Dividend yield
NoneSupha Pharmachem Limited does not currently pay a dividend.
Revenue growth
-90%Revenue fell 90% in the year to Mar 2025, and shrank 7% a year on average over 3 years.
Profit growth
-93%Net profit fell 93% in the year to Mar 2025, and grew 25% a year on average over 3 years.
Profit margin
0.5%Supha Pharmachem Limited keeps ₹1 of every ₹100 of revenue as net profit.
Cash quality
-537.4×Cash from Supha Pharmachem Limited's business was -537.4× its reported profit in the year to Mar 2025 — the business used cash even though it reported a profit.
Interest cover
0.2×Supha Pharmachem Limited's operating profit covered its interest costs 0.2 times in the year to Mar 2025.
Cash vs debt
Net debtSupha Pharmachem Limited had ₹43 Cr more debt than cash (net debt) at Mar 2025.
Questions
What is Supha Pharmachem Limited's P/E ratio?
Investors pay ₹1.9 for every ₹1 of Supha Pharmachem Limited's yearly profit, lower than almost all Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Supha Pharmachem Limited: ₹22 Cr ÷ ₹105 Cr (30 Sep 2025) = 0.2.
What is Supha Pharmachem Limited's return on equity?
Supha Pharmachem Limited earned 16.2% on its shareholders' money over the last year, higher than 61% of Healthcare companies in India.
How much does Supha Pharmachem Limited owe compared with what it owns?
Supha Pharmachem Limited owes ₹0.94 for every ₹1 it owns (high), higher than almost all Healthcare companies in India.
Does Supha Pharmachem Limited pay a dividend?
No. Supha Pharmachem Limited does not currently pay a dividend.
Is Supha Pharmachem Limited's revenue growing?
Revenue fell 90% in the year to Mar 2025, and shrank 7% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.